NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE
Post# of 341
(Total Views: 160)
Posted On: 05/10/2022 4:16:01 PM
NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Kernel Share Preliminary Results from Flow Feasibility Study
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its partner Kernel, are reporting preliminary data that confirm the ability of Kernel’s quantitative neuroimaging technology, Flow, to successfully measure neuro-effect of ketamine. Kernel is a leader in noninvasive neuroimaging. According to the announcement, results of a Cybin-sponsored feasibility study indicate that ketamine-induced changes in functional connectivity continued for several days after administration. Specifically, Kernel Flow successfully measured the neuro-effect of ketamine over 11 days (baseline at Days 1-5, dosing at Day 6, follow-up at Days 7-11); in addition, the results confirmed changes in functional connectivity that align with current scientific research. “Kernel’s Flow technology is revolutionary in the field of brain imaging as it is the first easy-to-use wearable that can collect real-time brain activity before, during and after a psychedelic experience,” said Cybin CEO Doug Drysdale in the press release. “Previously, studies had to rely on subjective patient reporting. By utilizing Flow, we will now be able to quantifiably gather real-time functional brain activity during our clinical and research studies evaluating psychedelic-based therapeutics. Measuring where and how psychedelics work in the brain unlocks new frontiers of discovery in this space. Most importantly, Kernel Flow will enable us to measure the duration of effect during a psychedelic experience, which will be pivotal in developing the most accurate and effective treatment regimens for patients. This technology is precisely what we need to accelerate the development of psychedelics into therapeutics.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its partner Kernel, are reporting preliminary data that confirm the ability of Kernel’s quantitative neuroimaging technology, Flow, to successfully measure neuro-effect of ketamine. Kernel is a leader in noninvasive neuroimaging. According to the announcement, results of a Cybin-sponsored feasibility study indicate that ketamine-induced changes in functional connectivity continued for several days after administration. Specifically, Kernel Flow successfully measured the neuro-effect of ketamine over 11 days (baseline at Days 1-5, dosing at Day 6, follow-up at Days 7-11); in addition, the results confirmed changes in functional connectivity that align with current scientific research. “Kernel’s Flow technology is revolutionary in the field of brain imaging as it is the first easy-to-use wearable that can collect real-time brain activity before, during and after a psychedelic experience,” said Cybin CEO Doug Drysdale in the press release. “Previously, studies had to rely on subjective patient reporting. By utilizing Flow, we will now be able to quantifiably gather real-time functional brain activity during our clinical and research studies evaluating psychedelic-based therapeutics. Measuring where and how psychedelics work in the brain unlocks new frontiers of discovery in this space. Most importantly, Kernel Flow will enable us to measure the duration of effect during a psychedelic experience, which will be pivotal in developing the most accurate and effective treatment regimens for patients. This technology is precisely what we need to accelerate the development of psychedelics into therapeutics.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)